Navigation Links
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
Date:11/12/2008

used for the polio eradication campaign in

Egypt. As a result, Egypt was declared polio-free by the WHO in

February 2006.

About M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides

The Institute of Poliomyelitis Research was established in 1955 by Michael Chumakov who became its first Director.

In 1960, the Institute included several laboratories and research departments from other research organizations and became Institute of Poliomyelitis and Viral Encephalitides.

Inactivated polio Salk vaccine has been produced in the Institute from 1956 to 1958, and since 1959 live attenuated polio vaccine administered orally (OPV) manufactured by the Institute has been used for mass vaccination campaigns.

Production technology of oral polio vaccine created in the Institute was the first to be certified by WHO for production and control of polio vaccines.

In the 1980's, new inactivated vaccine against tick-born encephalitis was developed by the Institute.

Now scientists are working on creation of human gamma immunoglobulin by new hybrid technology.

Vaccines against rabies and hepatitis A were also developed in research laboratories of M.P. Chumakov Institute and other Russian manufacturers produce those vaccines for mass vaccination.

The Institute has an exclusive advantage of close coordination between research and industrial operations. Scientists are involved in creating new vaccines and also new technologies for mass production.

The research department of M. P. Chumakov Institute includes 18 laboratories with 91 research scientists, including four academicians. The Institute produces live polio vaccine, vaccine against tick-born encephalitis, rabies, yellow fever, and measles.

About poliomyelitis

Poliomyelitis (polio) is a highly infectious disease caused by a virus that invades the nervous system and can cause severe paralysis. The virus enters the body through
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
2. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
3. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
4. Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors
5. Chemical Lifecycle Management Chooses Chemical Safety's EMS Software
6. Arcadia Radiology Medical Group Chooses AMICAS
7. Canadas Largest Urban Community Hospital Chooses Chyma(TM) On-Call Physician Scheduling Technology
8. Australia Chooses Cardiac Science to Equip Its Defence Force
9. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... members will be attending Pharma Ed Resources upcoming educational seminar and training ... industry leading speakers, this timely conference will provide Updates & Case Studies on ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... 500th patient was supported with the,Berlin Heart EXCOR(R) Pediatric ... the first implantation of the device in 1990. The,patient, ... Memorial,Hospital in Chicago and has been successfully transplanted in ... been diagnosed a few weeks after birth with left,ventricular ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
... Quest Diagnostics scientists will present results of three ... diagnosis and treatment of chronic myeloid leukemia (CML) and ... American Society of Clinical Oncology (ASCO), scheduled for May ... Incorporated (NYSE: DGX ) is the world,s ...
Cached Biology Technology:500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 3Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 4Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 5
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... mixing it with sugar, making thick jams that last ... Institute of Standards and Technology (NIST) have discovered* a ... the life of many things including vaccines, food and ... addition to jams, sugars are often used to preserve ...
... unlucky encounter with a crab,s pinchers, consider that the ... times harder than acrylic glass and extremely fracture resistant, ... the U.S. West Coast may have had close encounters ... in a paper published online in advance of regular ...
... not just the climate that is struggling with what humans ... the pressure as well, according to Professor Greg Gibson,s recently ... a Clash Between Our Genes and Modern Life Is Making ... Sciences, suggests the increased rates of diseases such as diabetes, ...
Cached Biology News:Probing and controlling 'molecular rattling' may mean better preservatives 2Crab claws pack strengthening bromide-rich biomaterial 2'It takes a genome: How a clash between our genes and modern life is making us sick' 2
DTT 50 l...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: